Abstract
Transcription activator-like effector nucleases (TALENs) are one of several types of programmable, engineered nucleases that bind and cleave specific DNA sequences. Cellular machinery repairs the cleaved DNA by introducing indels. In this review, we emphasize the potential, explore progress, and identify challenges in using TALENs as a therapeutic tool to treat HIV infection. TALENs have less off-target editing and can be more effective at tolerating HIV escape mutations than CRISPR/Cas-9. Scientists have explored TALEN-mediated editing of host genes such as viral entry receptors (CCR5 and CXCR4) and a protein involved in proviral integration (LEDGF/p75). Viral targets include the proviral DNA, particularly focused on the long terminal repeats. Major challenges with translating gene therapy from bench to bedside are improving cleavage efficiency and delivery, while minimizing off-target editing, cytotoxicity, and immunogenicity. However, rapid improvements in TALEN technology are enhancing cleavage efficiency and specificity. Therapeutic testing in animal models of HIV infection will help determine whether TALENs are a viable HIV treatment therapy. TALENs or other engineered nucleases could shift the therapeutic paradigm from life-long antiretroviral therapy toward eradication of HIV infection.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Agosto LM, Yu JJ, Liszewski MK et al (2009) The CXCR4-tropic human immunodeficiency virus envelope promotes more-efficient gene delivery to resting CD4+ T Cells than the vesicular stomatitis virus glycoprotein G envelope. J Virol 83:8153–8162. doi:10.1128/JVI.00220-09
Akkina R, Berges BK, Palmer BE et al (2011) Humanized Rag1−/− γc−/− mice support multilineage hematopoiesis and are susceptible to HIV-1 infection via systemic and vaginal routes. PLoS ONE 6:e20169. doi:10.1371/journal.pone.0020169
Aldrovandi GM, Feuer G, Gao L et al (1993) The SCID-hu mouse as a model for HIV-1 infection. Nature 363:732–736. doi:10.1038/363732a0
Allers K, Schneider T (2015) CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy. Curr Opin Virol 14:24–29. doi:10.1016/j.coviro.2015.06.007
Ayuso E (2016) Manufacturing of recombinant adeno-associated viral vectors: new technologies are welcome. Mol Ther Methods Clin Dev 3:15049. doi:10.1038/mtm.2015.49
Bedell VM, Wang Y, Campbell JM et al (2012) In vivo genome editing using high efficiency TALENs. Nature 491:114–118. doi:10.1038/nature11537
Benkirane M, Jin DY, Chun RF et al (1997) Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 272:30603–30606
Berges BK, Rowan MR (2011) The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment. Retrovirology 8:65. doi:10.1186/1742-4690-8-65
Berges BK, Wheat WH, Palmer BE et al (2006) HIV-1 infection and CD4 T cell depletion in the humanized Rag2−/− gamma c−/− (RAG-hu) mouse model. Retrovirology 3:76. doi:10.1186/1742-4690-3-76
Berges BK, Akkina SR, Folkvord JM et al (2008) Mucosal transmission of R5 and X4 tropic HIV-1 via vaginal and rectal routes in humanized Rag2−/−gammac −/− (RAG-hu) mice. Virology 373:342–351. doi:10.1016/j.virol.2007.11.020
Berges BK, Akkina SR, Remling L, Akkina R (2010) Humanized Rag2(−/−)gammac(−/−) (RAG-hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology 397:100–103. doi:10.1016/j.virol.2009.10.034
Boch J, Scholze H, Schornack S et al (2009) Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326:1509–1512. doi:10.1126/science.1178811
Bogdanove AJ, Schornack S, Lahaye T (2010) TAL effectors: finding plant genes for disease and defense. Curr Opin Plant Biol 13:394–401
Brown MJ, Murray KA (2006) Phenotyping of genetically engineered mice: humane, ethical, environmental, and husbandry issues. ILAR J 47:118–123
Budhagatapalli N, Rutten T, Gurushidze M et al (2015) Targeted modification of gene function exploiting homology-directed repair of TALEN-mediated double-strand breaks in Barley. G3 (Bethesda) 5:1857–1863. doi:10.1534/g3.115.018762
Bultmann S, Morbitzer R, Schmidt CS et al (2012) Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res 40:5368–5377. doi:10.1093/nar/gks199
Cermak T, Doyle EL, Christian M et al (2011) Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 39:e82. doi:10.1093/nar/gkr218
Cermak T, Starker CG, Voytas DF (2015) Efficient design and assembly of custom TALENs using the Golden Gate platform. Methods Mol Biol 1239:133–159. doi:10.1007/978-1-4939-1862-1_7
Cermáková K, Tesina P, Demeulemeester J et al (2014) Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia. Cancer Res 74:5139–5151. doi:10.1158/0008-5472.CAN-13-3602
Chen S, Oikonomou G, Chiu CN et al (2013) A large-scale in vivo analysis reveals that TALENs are significantly more mutagenic than ZFNs generated using context-dependent assembly. Nucleic Acids Res 41:2769–2778. doi:10.1093/nar/gks1356
Cherepanov P, Ambrosio ALB, Rahman S et al (2005) Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci USA 102:17308–17313. doi:10.1073/pnas.0506924102
Choudhary SK, Rezk NL, Ince WL et al (2009) Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2−/−{gamma}c−/− mouse. J Virol 83:8254–8258. doi:10.1128/JVI.00580-09
Christ F, Shaw S, Demeulemeester J et al (2012) Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother 56:4365–4374. doi:10.1128/AAC.00717-12
Christian M, Cermak T, Doyle EL et al (2010) Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 186:757–761. doi:10.1534/genetics.110.120717
Chun T-W, Justement JS, Murray D et al (2010) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 24:2803–2808. doi:10.1097/QAD.0b013e328340a239
Cornu TI, Cathomen T (2010) Quantification of zinc finger nuclease-associated toxicity. Methods Mol Biol 649:237–245. doi:10.1007/978-1-60761-753-2_14
Cornu TI, Mussolino C, Bloom K, Cathomen T (2015) Editing CCR5: a novel approach to HIV gene therapy. Adv Exp Med Biol 848:117–130. doi:10.1007/978-1-4939-2432-5_6
Cradick TJ, Fine EJ, Antico CJ, Bao G (2013) CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res 41:9584–9592. doi:10.1093/nar/gkt714
Cronin J, Zhang X-Y, Reiser J (2005) Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5:387–398
Dean M, Carrington M, Winkler C et al (1996) Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856–1862. doi:10.1126/science.273.5283.1856
Ding Q, Lee Y-K, Schaefer EAK et al (2012) A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell. doi:10.1016/j.stem.2012.11.011
Doyle EL, Booher NJ, Standage DS et al (2012) TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res 40:W117–122. doi:10.1093/nar/gks608
Doyon Y, Vo TD, Mendel MC et al (2011) Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods 8:74–79. doi:10.1038/nmeth.1539
Drake MJ, Bates P (2015) Application of gene-editing technologies to HIV-1. Curr Opin HIV AIDS 10:123–127. doi:10.1097/COH.0000000000000139
Ebina H, Kanemura Y, Misawa N et al (2015) A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS ONE. doi:10.1371/journal.pone.0120047
Fadel HJ, Morrison JH, Saenz DT et al (2014) TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism. J Virol 88:9704–9717. doi:10.1128/JVI.01397-14
Fine EJ, Cradick TJ, Zhao CL et al (2014) An online bioinformatics tool predicts zinc finger and TALE nuclease off-target cleavage. Nucleic Acids Res 42:e42. doi:10.1093/nar/gkt1326
Finkelshtein D, Werman A, Novick D et al (2013) LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci USA 110:7306–7311. doi:10.1073/pnas.1214441110
Geng X, Doitsh G, Yang Z et al (2014) Efficient delivery of lentiviral vectors into resting human CD4 T cells. Gene Ther 21:444–449. doi:10.1038/gt.2014.5
Gérard A, Ségéral E, Naughtin M et al (2015) The Integrase cofactor LEDGF/p75 associates with Iws1 and Spt6 for postintegration silencing of HIV-1 Gene expression in latently infected cells. Cell Host Microbe 17:107–117. doi:10.1016/j.chom.2014.12.002
Grau J, Wolf A, Reschke M et al (2013) Computational predictions provide insights into the biology of TAL effector target sites. PLoS Comput Biol 9:e1002962. doi:10.1371/journal.pcbi.1002962
Gu W-G (2015) Genome editing-based HIV therapies. Trends Biotechnol 33:172–179. doi:10.1016/j.tibtech.2014.12.006
Guilinger JP, Pattanayak V, Reyon D et al (2014) Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat Methods 11:429–435. doi:10.1038/nmeth.2845
Guo J, Gaj T, Barbas CF (2010) Directed evolution of an enhanced and highly efficient FokI cleavage domain for zinc finger nucleases. J Mol Biol 400:96–107. doi:10.1016/j.jmb.2010.04.060
Han Y, Li Q (2016) Application progress of CRISPR/Cas9 genome editing technology in the treatment of HIV-1 infection. Yi Chuan 38:9–16. doi:10.16288/j.yczz.15-284
Händel E-M, Cathomen T (2011) Zinc-finger nuclease based genome surgery: it’s all about specificity. Curr Gene Ther 11:28–37
Hanoun N, Gayral M, Pointreau A et al (2016) Initial characterization of integrase-defective lentiviral vectors for pancreatic cancer gene therapy. Hum Gene Ther 27:184–192. doi:10.1089/hum.2015.151
Hauber I, Hofmann-Sieber H, Chemnitz J et al (2013) Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice. PLoS Pathog 9:e1003587. doi:10.1371/journal.ppat.1003587
Heigwer F, Kerr G, Walther N et al (2013) E-TALEN: a web tool to design TALENs for genome engineering. Nucleic Acids Res. doi:10.1093/nar/gkt789
Holkers M, Cathomen T, Gonçalves MAFV (2014) Construction and characterization of adenoviral vectors for the delivery of TALENs into human cells. Methods 69:179–187. doi:10.1016/j.ymeth.2014.02.017
Holt N, Wang J, Kim K et al (2010) Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28:839–847. doi:10.1038/nbt.1663
Hou P, Chen S, Wang S et al (2015) Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep 5:15577. doi:10.1038/srep15577
Huang YX, Paxton WA, Wolinsky SM et al (1996) The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2:1240–1243. doi:10.1038/nm1196-1240
Hütter G, Bodor J, Ledger S et al (2015) CCR5 targeted cell therapy for HIV and prevention of viral escape. Viruses 7:4186–4203. doi:10.3390/v7082816
Ince WL, Zhang L, Jiang Q et al (2010) Evolution of the HIV-1 env gene in the Rag2−/− gammaC−/− humanized mouse model. J Virol 84:2740–2752. doi:10.1128/JVI.02180-09
Ishida K, Gee P, Hotta A (2015) Minimizing off-target mutagenesis risks caused by programmable nucleases. Int J Mol Sci 16:24751–24771. doi:10.3390/ijms161024751
Jamieson BD, Aldrovandi GM, Zack JA (1996) The SCID-hu mouse: an in vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS. Semin Immunol 8:215–221. doi:10.1006/smim.1996.0027
Jia J, Jin Y, Bian T et al (2014) Bacterial delivery of TALEN proteins for human genome editing. PLoS ONE. doi:10.1371/journal.pone.0091547
Josefsson L, King MS, Makitalo B et al (2011) Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc Natl Acad Sci 108:11199–11204. doi:10.1073/pnas.1107729108
Kim Y, Kweon J, Kim A et al (2013) A library of TAL effector nucleases spanning the human genome. Nat Biotechnol 31:251–258. doi:10.1038/nbt.2517
Koradi R, Billeter M, Wüthrich K (1996) MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 14(51–55):29–32
Kordelas L, Verheyen J, Esser S (2014) Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med 371:880–882. doi:10.1056/NEJMc1405805
Le T, Farrar J, Shikuma C (2011) Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 25:871–872. doi:10.1097/QAD.0b013e32834490b1 (author reply 872–873)
Levy JA (1993) Pathogenesis of human immunodeficiency virus infection. Microbiol Rev 57:183–289
Li M-J, Kim J, Li S et al (2005) Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 12:900–909. doi:10.1016/j.ymthe.2005.07.524
Li T, Huang S, Jiang W et al (2011) TAL nucleases (TALNs): hybrid proteins composed of TAL effectors and FokI DNA-cleavage domain. Nucleic Acids Res 39:359–372. doi:10.1093/nar/gkq704
Lin Y, Fine EJ, Zheng Z et al (2014) SAPTA: a new design tool for improving TALE nuclease activity. Nucleic Acids Res 42:e47. doi:10.1093/nar/gkt1363
Liu J, Gaj T, Patterson JT et al (2014) Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering. PLoS ONE 9:e85755. doi:10.1371/journal.pone.0085755
Liu C, Ma X, Liu B et al (2015) HIV-1 functional cure: will the dream come true? BMC Med. doi:10.1186/s12916-015-0517-y
Lopalco L (2010) CCR5: from natural resistance to a new anti-HIV strategy. Viruses 2:574–600. doi:10.3390/v2020574
Ma AC, Lee HB, Clark KJ, Ekker SC (2013) High efficiency in vivo genome engineering with a simplified 15-RVD GoldyTALEN design. PLoS ONE. doi:10.1371/journal.pone.0065259
Mahfouz M, Li L, Shamimuzzaman M et al (2011) De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks. Proc Natl Acad Sci USA 108:2623–2628. doi:10.1073/pnas.1019533108
Mak AN-S, Bradley P, Cernadas RA et al (2012) The crystal structure of TAL effector PthXo1 bound to its DNA target. Science 335:716–719. doi:10.1126/science.1216211
Malam Y, Loizidou M, Seifalian AM (2009) Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30:592–599. doi:10.1016/j.tips.2009.08.004
Maldarelli F, Wu X, Su L et al (2014) Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345:179–183. doi:10.1126/science.1254194
Manjunath N, Yi G, Dang Y, Shankar P (2013) Newer gene editing technologies toward HIV gene therapy. Viruses 5:2748–2766. doi:10.3390/v5112748
McClure J, Schmidt AM, Rey-Cuille MA et al (2000) Derivation and characterization of a highly pathogenic isolate of human immunodeficiency virus type 2 that causes rapid CD4+ cell depletion in Macaca nemestrina. J Med Primatol 29:114–126
Miller JC, Tan S, Qiao G et al (2011) A TALE nuclease architecture for efficient genome editing. Nat Biotech 29:143–148. doi:10.1038/nbt.1755
Miller JC, Zhang L, Xia DF et al (2015) Improved specificity of TALE-based genome editing using an expanded RVD repertoire. Nat Methods 12:465–471. doi:10.1038/nmeth.3330
Mock U, Machowicz R, Hauber I et al (2015) mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5. Nucleic Acids Res 43:5560–5571. doi:10.1093/nar/gkv469
Montague TG, Cruz JM, Gagnon JA et al (2014) CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucl Acids Res gku410. doi:10.1093/nar/gku410
Moscou MJ, Bogdanove AJ (2009) A simple cipher governs DNA recognition by TAL effectors. Science 326:1501. doi:10.1126/science.1178817
Mosier DE (1996) Human immunodeficiency virus infection of human cells transplanted to severe combined immunodeficient mice. Adv Immunol 63:79–125
Mosier DE, Gulizia RJ, Baird SM et al (1991) Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251:791–794
Mukherjee R, Plesa G, Sherrill-Mix S et al (2010) HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model. Mol Ther 18:803–811. doi:10.1038/mt.2009.316
Mussolino C, Morbitzer R, Lütge F et al (2011) A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res 39:9283–9293. doi:10.1093/nar/gkr597
Nakajima K, Yaoita Y (2013) Comparison of TALEN scaffolds in Xenopus tropicalis. Biol Open 2:1364–1370. doi:10.1242/bio.20136676
Ousterout DG, Perez-Pinera P, Thakore PI et al (2013) Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients. Mol Ther 21:1718–1726. doi:10.1038/mt.2013.111
Reardon S (2014) Gene-editing method tackles HIV in first clinical test. Nature. doi:10.1038/nature.2014.14813
Reyon D, Tsai SQ, Khayter C et al (2012) FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 30:460–465. doi:10.1038/nbt.2170
Ru R, Yao Y, Yu S et al (2013) Targeted genome engineering in human induced pluripotent stem cells by penetrating TALENs. Cell Regen (Lond). doi:10.1186/2045-9769-2-5
Sakuma T, Yamamoto T (2016) Engineering customized TALENs using the platinum gate TALEN kit. Methods Mol Biol 1338:61–70. doi:10.1007/978-1-4939-2932-0_6
Sakuma T, Ochiai H, Kaneko T et al (2013) Repeating pattern of non-RVD variations in DNA-binding modules enhances TALEN activity. Sci Rep. doi:10.1038/srep03379
Sanchez FM, Berges BK (2013) Characterization of HIV-1 infection in the humanized Rag2−/−γc−/− mouse model. Methods Mol Biol 1031:215–222. doi:10.1007/978-1-62703-481-4_24
Sather BD, Ibarra GSR, Sommer K et al (2015) Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med 7:307ra156. doi:10.1126/scitranslmed.aac5530
Sato K, Izumi T, Misawa N et al (2010) Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol 84:9546–9556. doi:10.1128/JVI.00823-10
Sato K, Takeuchi JS, Misawa N et al (2014) APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLoS Pathog 10:e1004453. doi:10.1371/journal.ppat.1004453
Schiffer JT, Aubert M, Weber ND et al (2012) Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol 86:8920–8936. doi:10.1128/JVI.00052-12
Schmid-Burgk JL, Schmidt T, Kaiser V et al (2013) A ligation-independent cloning technique for high-throughput assembly of transcription activator—like effector genes. Nat Biotechnol 31:76–81. doi:10.1038/nbt.2460
Schmid-Burgk JL, Schmidt T, Hornung V (2015) Ligation-independent cloning (LIC) assembly of TALEN genes. Methods Mol Biol 1239:161–169. doi:10.1007/978-1-4939-1862-1_8
Schroers R, Hildebrandt Y, Hasenkamp J et al (2004) Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors. Exp Hematol 32:536–546. doi:10.1016/j.exphem.2004.03.010
Shultz LD, Ishikawa F, Greiner DL (2007) Humanized mice in translational biomedical research. Nat Rev Immunol 7:118–130. doi:10.1038/nri2017
Shun M-C, Raghavendra NK, Vandegraaff N et al (2007) LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev 21:1767–1778. doi:10.1101/gad.1565107
Strong CL, Guerra HP, Mathew KR et al (2015) Damaging the integrated HIV proviral DNA with TALENs. PLoS ONE. doi:10.1371/journal.pone.0125652
Summerford C, Samulski RJ (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438–1445
Sun N, Liang J, Abil Z, Zhao H (2012a) Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. Mol BioSyst 8:1255–1263. doi:10.1039/C2MB05461B
Sun N, Liang J, Abil Z, Zhao H (2012b) Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. Mol BioSyst 8:1255–1263. doi:10.1039/C2MB05461B
Sutherland HG, Newton K, Brownstein DG et al (2006) Disruption of Ledgf/Psip1 results in perinatal mortality and homeotic skeletal transformations. Mol Cell Biol 26:7201–7210. doi:10.1128/MCB.00459-06
Tebas P, Stein D, Tang WW et al (2014) Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370:901–910. doi:10.1056/NEJMoa1300662
Tesson L, Remy S, Ménoret S et al (2016) Genome editing in rats using TALE nucleases. Methods Mol Biol 1338:245–259. doi:10.1007/978-1-4939-2932-0_18
Valton J, Dupuy A, Daboussi F et al (2012) Overcoming transcription activator-like effector (TALE) DNA binding domain sensitivity to cytosine methylation. J Biol Chem 287:38427–38432. doi:10.1074/jbc.C112.408864
Valton J, Cabaniols J-P, Galetto R et al (2014) Efficient strategies for TALEN-mediated genome editing in mammalian cell lines. Methods 69:151–170. doi:10.1016/j.ymeth.2014.06.013
Wang Z, Pan Q, Gendron P et al (2016) CRISPR/Cas9-Derived Mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep 15:481–489. doi:10.1016/j.celrep.2016.03.042
Ye L, Wang J, Beyer AI et al (2014) Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 111:9591–9596. doi:10.1073/pnas.1407473111
Yukl SA, Boritz E, Busch M et al (2013) Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 9:e1003347. doi:10.1371/journal.ppat.1003347
Zhang Z, Zhang S, Huang X et al (2013) Rapid assembly of customized TALENs into multiple delivery systems. PLoS ONE 8:e80281. doi:10.1371/journal.pone.0080281
Zheng Y, Yu F, Wu Y et al (2015) Broadening the versatility of lentiviral vectors as a tool in nucleic acid research via genetic code expansion. Nuclei Acids Res 43:e73–e73. doi:10.1093/nar/gkv202
Zimmerman PA, BucklerWhite A, Alkhatib G et al (1997) Inherited resistance to HIV-1 conferred by an inactivating mutation in. Mol Med 3:23–36
Acknowledgments
Grants from the National Institutes of Health (R56 AI109156) and the Nevada Governors Office of Economic Development supported this work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Martin R. Schiller and Christy L. Strong have a patent pending for using TALENs to treat HIV, and thus have a potential conflict of interest.
Rights and permissions
About this article
Cite this article
Benjamin, R., Berges, B.K., Solis-Leal, A. et al. TALEN gene editing takes aim on HIV. Hum Genet 135, 1059–1070 (2016). https://doi.org/10.1007/s00439-016-1678-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00439-016-1678-2